Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group
William W. Tseng(Brigham and Women's Hospital), Andrew J. Wagner(Dana-Farber Cancer Institute), David Gyorki(The University of Melbourne), Dimitri Tzanis(Université Paris Cité), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Hayden Snow(Peter MacCallum Cancer Centre), Carol J. Swallow(University Health Network), Myles Smith(Royal Marsden NHS Foundation Trust), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Anant Desai(NIHR Surgical Reconstruction and Microbiology Research Centre), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Vittorio Quagliuolo(Humanitas University), Toufik Bouhadiba(Institut Curie), Kenneth Cardona(Emory University), Wendy Johnston(University of Toronto), Rebecca A. Gladdy(Princess Margaret Cancer Centre), M. Fau(Biocodex (France)), Rick L. Haas(Leiden University Medical Center), Kyo Won Lee(Samsung Medical Center), John E. Mullinax(Moffitt Cancer Center), Valerie P. Grignol(Ohio State University Hospital), Khin Thway(Royal Marsden Hospital), Robin L. Jones(Institute of Cancer Research), Giovanni Grignani(Candiolo Cancer Institute), Rachel K. Voss(Moffitt Cancer Center), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), Roberta Sanfilippo(Fondazione IRCCS Istituto Nazionale dei Tumori), D. Strauß(Royal Marsden Hospital), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Winan J. van Houdt(Diakonessenhuis hospital), Markus Albertsmeier(LMU Klinikum), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Jeffrey M. Farma(Fox Chase Cancer Center), Christina L. Roland(The University of Texas MD Anderson Cancer Center), Andrew Hayes(Royal Marsden NHS Foundation Trust), Ricardo González(Moffitt Cancer Center), Max L. Almond(Queen Elizabeth Hospital Birmingham), Elizabeth H. Baldini(Dana-Farber Cancer Institute), Elisabetta Pennacchioli(European Institute of Oncology), Charles Catton(University of Toronto), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology)
Cited by 49
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k